EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Nektar Therapeutics (NKTR) had EBIT Margin of -268.63% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$11.79M |
|
$-35.52M |
|
-- |
|
$11.79M |
|
$43.46M |
|
$-31.67M |
|
$-3.35M |
|
$-35.02M |
|
$-35.02M |
|
$-34.99M |
|
$-35.52M |
|
$-35.52M |
|
$-34.99M |
|
$-31.67M |
|
$-32.91M |
|
18.95M |
|
18.95M |
|
$-1.87 |
|
$-1.87 |
|
| Balance Sheet Financials | |
$281.36M |
|
$2.83M |
|
$19.99M |
|
$301.35M |
|
$66.34M |
|
-- |
|
$149.92M |
|
$216.26M |
|
$85.09M |
|
$85.09M |
|
$85.09M |
|
19.65M |
|
| Cash Flow Statement Financials | |
$-143.55M |
|
$-1.57M |
|
$141.90M |
|
$44.25M |
|
$41.03M |
|
$-3.22M |
|
$10.46M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.24 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-268.63% |
|
|
EBIT Margin |
-268.63% |
-- |
|
-297.04% |
|
-301.29% |
|
$-143.71M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
-- |
|
-- |
|
-41.75% |
|
-41.75% |
|
-11.79% |
|
-41.75% |
|
$4.33 |
|
$-7.58 |
|
$-7.58 |
|